Articles tagged with Cancer Patients
A protein called interleukin 6 (IL-6) plays a significant role in the spread of colorectal cancer to other parts of the body, particularly the liver. Suppressing IL-6 expression can enhance anti-tumor immune functions and improve patient survival.
Researchers found that both strands of microRNA coordinate to act on the same cancer pathways, driving aggressiveness and growth. MicroRNAs miR-30a and miR-145 were identified as key players in keeping cancers in check, impacting patient survival.
This observational study analyzed 112 studies to examine the association between cancer risk in patients with psoriasis or psoriatic arthritis. The findings suggest that these patients may be at higher risk of specific cancers, including melanoma and non-melanoma skin cancers.
Adult lymphoma patients treated with CAR-T therapy reported improved physical and social function, as well as better emotional and mental health. The study suggests that CAR-T may not only extend survival but also improve quality of life after treatment.
Researchers found that white patients received earlier treatment and had better survival rates than black patients, with hospitals having a significant impact on outcomes. The study suggests structural issues at the hospital level influence differences in cancer outcomes across racial groups.
For the first time, a cancer patient has given birth to a healthy baby using lab-matured eggs that were frozen, thawed, and fertilized five years later. The breakthrough achievement demonstrates the potential of in vitro maturation (IVM) for fertility preservation in cancer patients.
Researchers developed a hydrogel that changes color with radiation exposure, allowing for painless dose monitoring on the skin. The gel is relatively inexpensive and can be used directly on the skin without complex handling.
A new study provides an unprecedented look at the molecular steps of endometrial cancer, offering insights into tumor aggressiveness and patient responses to treatment. The research also suggests potential new roles for already-approved drugs targeting proteins like CDK12, SMARCA4, and PML in other types of cancer.
Researchers identified 34 patients with therapy-associated polyposis (TAP), developing colorectal growths despite not having a hereditary susceptibility. The study found TAP mimics familial polyposis but is biologically distinct, suggesting multiple biological pathways involved in its development.
Researchers found that oral cancers can reprogram nerves to grow into tumors, changing their function and fuelling growth. The team discovered that adrenergic nerves, involved in stress response, are susceptible to drugs used to treat high blood pressure and irregular heartbeats.
Researchers analyzed genomes of nearly 50 tumor samples from angiosarcoma patients and found dozens of mutated genes, including new clues about therapeutic possibilities for some subtypes. The study suggests that drugs approved for other types of cancer might be useful in treating angiosarcoma.
Researchers at Huntsman Cancer Institute developed a novel CAR T cell therapy targeting CD229, a molecule present on cancer cells and stem cells in patients with multiple myeloma. Laboratory tests showed promising results, including the ability to kill mature multiple myeloma cells and myeloma stem cells.
Researchers have shown that patients with low rectal cancer can safely choose to postpone invasive surgery after a course of radio- and chemotherapy. In fact, the majority of patients do not show regrowth of the tumor after two years of surveillance, and those who do, achieve similar outcomes as immediate surgery.
A new study found that breast cancer treatment among women who test positive for an inherited genetic mutation is less in line with practice guidelines, particularly for radiation therapy and chemotherapy. The researchers found distinct differences in surgery, radiation, and chemotherapy treatments among BRCA-positive patients.
A study of 125,500 Danish patients with atrial fibrillation found that those who experienced bleeding were between 11 and 24 times more likely to be diagnosed with bowel cancer. Patients who had gastrointestinal bleeding should always be offered meticulous clinical examination regardless of anticoagulant treatment.
This study found that the addition of nimotuzumab to weekly cisplatin-radiation significantly improves outcomes, including overall survival, in locally advanced head and neck cancer patients with HPV negative oropharyngeal cancers. The study compared these outcomes with a control group receiving only cisplatin-radiation.
Researchers have successfully edited immune cells using CRISPR technology in a U.S. clinical trial, demonstrating sustained anti-tumor function and persistence of the edited cells for up to nine months. The approach has shown promise as a potential treatment for various diseases previously untreatable or incurable.
Researchers have identified new genetic drivers of cancer in non-coding regions of the genome, finding that many cancers are driven by mutations in these areas. The study confirmed previously reported drivers and invalidated others, while also identifying novel putative driver rearrangements near genes called AKR1C.
A recent study published in Geriatrics & Gerontology International found that cancer patients with dementia were less likely to achieve a good death compared to those without. The study's authors emphasize the importance of enhancing end-of-life care discussions and improving symptom management for these patients.
A study of over 2,500 tumor genomes reveals that most cancer cells use alternative mechanisms to lengthen their telomeres, increasing their lifespan. The researchers discovered unique variations in these telomere sequences and their integration into the genome, which may hold clues for developing targeted treatments.
Researchers have identified 81 distinct mutational signatures in human cancer genomes that can help reveal the origins and development of various types of cancer. These signatures can provide insight into factors that have mutated a cell's genetic material and inform new strategies to prevent, diagnose and treat the disease.
The Pan-Cancer Project has created the most comprehensive map of cancer genomes to date, improving our understanding of cancer and its diagnosis. Researchers have identified key regions controlling gene expression and discovered a 'carbon dating' method to pinpoint mutations in tumors years before they appear.
Researchers found CNVs to be genomic modifiers of ASD/DD risk in individuals with PHTS, providing insight into the disorder's clinical outcomes and potential predictors for medical management. The study suggests CNV burden analysis may aid in predicting clinical outcomes for other clinically heterogeneous disorders.
Researchers have established new guidelines for analyzing patient-reported outcomes (PROs) in cancer clinical trials, aiming to provide more consistent and comparable Quality of Life (QoL) results. The adoption of these standards will ensure that trial results are more reliable and beneficial for patients.
A University of Colorado Cancer Center study found that patients with locally advanced rectal cancer who received lower-than-recommended doses of neoadjuvant chemotherapy experienced a complete response and tumor shrinkage similar to those receiving the full dose.
Research found that high CO2 levels drive the aggressiveness of pancreatic tumor cells and their resistance to treatment. Increasing CO2 levels in cell cultures also showed increased growth and aggression, while common chemotherapeutic agents and radiation therapy were less effective against high-CO2-cultured cells.
A long-term follow-up study found that psilocybin therapy significantly improves emotional and existential distress in cancer patients, with sustained benefits lasting nearly five years. The study's results suggest that psilocybin may provide a useful tool for enhancing the effectiveness of psychotherapy.
A new research team will focus on detecting gastric cancer at an early stage, potentially saving thousands of lives. The team will use advanced technologies to identify biomarkers in the blood that indicate the presence of gastric cancer.
New research from UT Southwestern Medical Center shows how AI can generate optimal treatment plans in near real-time, streamlining the process and reducing delays of up to a week. This can decrease the odds of cancer spreading by 12-14%.
SU2C's new health equity initiative aims to reduce racial and ethnic disparities in cancer research, addressing socio-economic, cultural, trust barriers that prevent minority participation. The organization requires grant proposals to include diverse patient recruitment and retention plans.
Researchers have discovered a two-drug combo that can counter resistance to a promising new breast cancer therapy. The combination of neratinib and everolimus effectively blocks the growth of cancer cells with HER2 mutations, providing a novel treatment option for patients with these types of cancers.
The GW Cancer Center is conducting a phase II clinical trial examining the safety and effectiveness of Libtayo in reducing tumor size and preventing recurrence in high-risk cutaneous squamous cell carcinoma. The study aims to enroll over 75 participants and build on preliminary results from similar trials.
The European Parliament has launched a new report on radioligand therapy, highlighting its potential to improve targeted cancer care. The report identifies barriers to adoption and recommends increasing multidisciplinary care and boosting real-world data collection.
Researchers found that only 0.1% of cancer patients were enrolled in clinical trials as their first course of therapy after diagnosis. White males with private health insurance and metastatic cancers are more likely to enroll, but the low enrollment rate is still troubling due to the potential for increased life expectancy.
Researchers at Cardiff University have discovered a new type of killer T-cell with a unique T-cell receptor (TCR) that recognizes and kills most human cancer cells while ignoring healthy cells. This breakthrough has the potential to create a 'one-size-fits-all' cancer therapy, targeting a wide range of cancers in all patients.
A new algorithm uses machine learning to identify genes that spur tumor growth by linking DNA mutations to altered functionality. The method can predict and validate cancer-driving genes in any database or real population sample.
A research team at Dartmouth's Norris Cotton Cancer Center has identified VISTA as a molecule that regulates immunity and limits the damage it can cause. Blocking VISTA may enhance the host's ability to make protective tumor-specific immune responses, leading to potential therapeutic response to cancer.
New research suggests lactate is a catalyst that triggers cancer forming process in mutated cells. The study's findings open a new door to better understand cancer at the metabolic level and could lead to targeted therapies.
A rapid diagnosis centre has reduced waiting times for patients with non-specific symptoms who may have cancer to under 6 days. The study also found that if the RDC runs at full capacity, Swansea Bay University Health Board could save £157,858 and gain 9.2 quality-adjusted life years.
Researchers at Ohio State University Wexner Medical Center suggest a new approach to treating advanced, progressing bile duct cancer. The study found that adding an mTOR inhibitor may re-sensitize tumor cells to FGFR inhibitors in patients who develop resistance to these agents.
A Phase III clinical trial found that eating seven or more servings of vegetables and fruits daily did not provide extra protection against prostate cancer. Despite this, a healthy diet rich in fruits and vegetables may help patients tolerate cancer treatments.
Researchers at Ohio State University Comprehensive Cancer Center discover a direct connection between thrombin and TGF-b1, a cytokine promoting tumor progression and suppressing immune responses. Blocking this mechanism prevents tumor resistance to immunotherapy and increases tumor-infiltrating immune cells.
A $300,000 grant will help UniSA researcher Dr Stephanie Reuter Lange explore how computer-based modelling can optimise cancer treatment and remove the need for expensive clinical trials. The goal is to tailor drug dosages to individual patients to maximise tumour response and minimise side effects.
Research shows that HPV-negative oropharynx cancer patients are at a significantly higher risk of dying from any cause within two years. In contrast, HPV-positive patients have a lower risk of dying from head and neck cancer and other types of cancer.
Researchers analyzed genome-scale data from male adolescents to understand changes in stem cells during puberty. They found that testosterone is crucial for maintaining mature testis development, and disruptions can lead to infertility and increased risk of testicular cancer.
A new study shows that the 21-gene recurrence score test, commonly used to predict disease recurrence and chemotherapy benefit in breast cancer patients, may also help determine whether radiation therapy is necessary. Patients with intermediate or high scores are more likely to see their cancer return and benefit from radiation.
Researchers found that surgically removing the entire tumor can boost median survival length from eight months to 16 months or more. The study analyzed data from 103 patients and suggests surgery may be a viable treatment option for brainstem high-grade gliomas, which are rare and deadly brain cancers.
The study found significant tumor shrinkage in two out of three patients with salivary gland tumors treated with T-DM1. The benefit lasted for at least two years in one patient, suggesting a promising activity for this rare cancer type.
A team of researchers at Dartmouth's Norris Cotton Cancer Center has collected real-time data to show that light is produced inside the eye during head and neck radiation therapy, elicitng a visual sensation. This evidence supports the idea that Cherenkov light emission from the eye can cause a visual effect.
A new study strengthens the link between vitamin E acetate and EVALI (e-cigarette or vaping product use-associated lung injury), finding it in BAL fluid from 48 of 51 EVALI patients but not healthy individuals. The CDC analyzed samples from 16 states and compared them to 99 healthy individuals.
A study published in JAMA Oncology found that proton therapy is just as effective as X-ray radiation therapy in treating cancer, but causes fewer side effects and lower hospitalization rates. This could lead to improved quality of life for patients and reduced healthcare costs.
Researchers found that younger patients with stomach cancer often present with more aggressive disease, a worse prognosis, and reduced effectiveness of traditional chemotherapy treatments. The study highlights the importance of increased awareness and early detection for this increasingly prevalent form of stomach cancer.
Researchers have developed a new approach to study the bone marrow in unprecedented resolution, revealing previously unknown cell types and their local environments. The study provides a novel basis for studying blood diseases such as leukemias and has made its dataset publicly accessible for further research.
A new study explores women's knowledge and perceptions of breast density and breast cancer screening across three states with varying notification laws. Women from all states had varying knowledge about their own breast density and breast density in general, and expressed a strong desire for more information.
A Hebrew University research team has discovered a potential link between the BCG vaccine and reduced Alzheimer's disease risk in cancer patients. The study found that those who received the BCG vaccine had significantly lower rates of developing Alzheimer's compared to those who did not.
Researchers are assembling the largest dataset of veterans with either condition or both to compare conditions and outcomes. They hope to find correlations between mental health and prostate cancer aggressiveness and explore biological risks like inflammation.
The Affordable Care Act provision allowing young adults to be covered under their parents' insurance led to improved care for colorectal cancer patients. Young adults diagnosed with stage IIB-IIIC colorectal cancer were 34% more likely to receive adjuvant chemotherapy post-ACA compared to pre-ACA.
The NCI-MATCH trial found a 36% response rate across various cancers with DNA mismatch repair deficiencies, including rare and uncommon tumor types. The results provide an important signal for further study and potential treatment options.
Researchers developed a new classification system for tumors based on genome sequencing, assigning patients to one of sixteen groups. The system provides important information for diagnosis and treatment, including potential responses to immunotherapy.
A systematic review and meta-analysis of 14 randomized clinical trials found evidence suggesting acupuncture and acupressure can reduce cancer pain. The studies showed varied but generally positive effects on pain reduction, with some suggesting improved outcomes in patients receiving acupuncture or acupressure.